Loading
Companies and public funders would pool money and scientists to crack the hardest cancer proteins, such as MYC and mutant p53, sharing everything openly until there is a real drug candidate, then competing on the final product.
A consortium on the Structural Genomics Consortium and Open Targets model, but aimed at the highest-value undruggable oncology targets: MYC, mutant p53 reactivation, non-G12C RAS alleles beyond current inhibitors, fusion oncoproteins, transcription-factor and phosphatase targets. Members fund shared structural biology, chemical biology, degrader and molecular glue platforms and open probe generation, with an agreement that all results are published without patents up to the point of a validated chemical series, after which members may file and compete. The public benefit is a decade of duplicated, secret failure replaced by a shared map of what does and does not work.
Shares Secrecy and intellectual property block collaboration, AI-driven drug & target discovery, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
Shares p53 / RB / cell-cycle checkpoint, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation), TP53.
Shares AI-driven drug & target discovery, p53 / RB / cell-cycle checkpoint, The undruggable drivers, TP53.
Shares KRAS roadmap: undruggable → G12C → pan-RAS, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK), KRAS.
Shares Broad Institute of MIT and Harvard, Secrecy and intellectual property block collaboration, The undruggable drivers.
Shares KRAS roadmap: undruggable → G12C → pan-RAS, The undruggable drivers, RAS / RAF / MEK / ERK (MAPK), KRAS.
Shares Broad Institute of MIT and Harvard, AI-driven drug & target discovery, The undruggable drivers.
Shares AI-driven drug & target discovery, PROTACs & molecular glues (targeted protein degradation), KRAS.